- Accueil >
- Publications >
- Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
Auteurs
S. Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, Domenico Ferraioli, Olfa Derbel, Alexandre Bodmer, Patrick Petignat, Beata Rak, Nicolas Chopin, Olivier Tredan, Pierre-Etienne Heudel, Sarah Stuckelberger, Pierre Meeus, Patrick Meraldi, Valeria Viassolo, Aurélie Ayme, Pierre O. Chappuis, Marc-Henri Stern, Claude Houdayer, Dominique Stoppa-Lyonnet, Adrien Buisson, Lisa Golmard, Valérie Bonadona, Isabelle Ray-Coquard
Résumé
Abstract
Purpose: BRCA2 plays a central role in homologous recombination by loading RAD51 on DNA breaks. The objective of this study is to determine whether the location of mutations in the RAD51-binding domain (RAD51-BD; exon 11) of BRCA2 gene affects the clinical outcome of ovarian cancer patients.
Experimental Design: A study cohort of 353 women with ovarian cancer who underwent genetic germline testing for BRCA1 and BRCA2 genes was identified. Progression-free survival (PFS), platinum-free interval (PFI), and overall survival (OS) were analyzed. The Cancer Genome Atlas (TCGA) cohort of ovarian cancer (n = 316) was used as a validation cohort.
Results: In the study cohort, 78 patients were carriers of germline mutations of BRCA2. After adjustment for FIGO stage and macroscopic residual disease, BRCA2 carriers with truncating mutations in the RAD51-BD have significantly prolonged 5-year PFS [58%; adjusted HR, 0.36; 95% confidence interval (CI), 0.20–0.64; P = 0.001] and prolonged PFI (29.7 vs. 15.5 months, P = 0.011), compared with noncarriers. BRCA2 carriers with mutations located in other domains of the gene do not have prolonged 5-year PFS (28%, adjusted HR, 0.67; 95% CI, 0.42–1.07; P = 0.094) or PFI (19 vs. 15.5 months, P = 0.146). In the TCGA cohort, only BRCA2 carriers harboring germline or somatic mutations in the RAD51-BD have prolonged 5-year PFS (46%; adjusted HR, 0.30; 95% CI, 0.13–0.68; P = 0.004) and 5-year OS (78%; adjusted HR, 0.09; 95% CI, 0.02–0.38; P = 0.001).
Conclusions: Among ovarian cancer patients, BRCA2 carriers with mutations located in the RAD51-BD (exon 11) have prolonged PFS, PFI, and OS. Clin Cancer Res; 24(2); 326–33. ©2017 AACR.
Membres
